Quick Answer
Edgewise Therapeutics, Inc. reported Operating Income of -$191.41 million for fiscal year 2025.
Edgewise Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$191.41M | -20.5% |
| 2024 | -$158.83M | -38.9% |
| 2023 | -$114.36M | -59.6% |
| 2022 | -$71.66M | -65.8% |
| 2021 | -$43.22M | -151.4% |
| 2020 | -$17.19M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$46.86M | -15.9% | -10.0% |
| June 30, 2025 | -$42.61M | -11.8% | +7.3% |
| March 31, 2025 | -$45.96M | -32.2% | -13.7% |
| September 30, 2024 | -$40.43M | -37.3% | -6.1% |
| June 30, 2024 | -$38.11M | -50.4% | -9.7% |
| March 31, 2024 | -$34.75M | -35.2% | -18.0% |
| September 30, 2023 | -$29.45M | -61.3% | -16.2% |
| June 30, 2023 | -$25.34M | -53.7% | +1.4% |
- Edgewise Therapeutics, Inc. showed a decrease of -20.5% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Edgewise Therapeutics, Inc.’s operating income has declined by 1013.3% (from -$17.19 million to -$191.41 million).
- The most recent figure is from Edgewise Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: